Development Of Interaction Test Data Generation Strategy With Input-Output Mapping Supports

Uniform strength t-way testing (where t represents interaction strength) forms the basis of interaction testing. However, t is rarely uniform in real world as not all interaction faults are solely constituted by these fixed t-interactions. Consequently, a general solution has been introduced: input-output based relationship interaction testing. Although useful, most existing strategy implementations are lacking in terms of the automated input-output mapping support (to translate the symbolic outputs back into actual data form) and test suite generation flexibility. In order to address these aforementioned issues, a non-deterministic input-output based relationship interaction testing strategy, AURA, has been developed. AURA strategy also integrated with post-processing automated input-output mapping support and flexible iteration control capability to support test suite generation flexibility. Experimental results indicated that AURA strategy is generating competitive test suite size against existing strategies (Density, ParaOrder, Union, TVG, PICT, AETG, ACA, GA-N, IPO-N, IPO, Jenny, SA and ACS). Specifically, this strategy is capable to generate the test suite size as optimized as other strategies for certain inputs. Lastly, the post-processing automated input-output mapping support and flexible iteration control capability are evaluated with experiments

The Design and Implementation of a Pairwise Strategy Supporting Constraints and Seeding Mechanism

This paper describes the design and development of a pairwise test data generation, called 2TG, supporting seeding and constraints. In doing so, a number of experiments are discussed in order to prove the correctness of the implementation

Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update

Large amounts of new data on the natural history and treatment of chronic hepatitis B virus (HBV) infection have become available since 2005. These include long-term follow-up studies in large community-based cohorts or asymptomatic subjects with chronic HBV infection, further studies on the role of HBV genotype/naturally occurring HBV mutations, treatment of drug resistance and new therapies. In addition, Pegylated interferon α2a, entecavir and telbivudine have been approved globally. To update HBV management guidelines, relevant new data were reviewed and assessed by experts from the region, and the significance of the reported findings were discussed and debated. The earlier “Asian-Pacific consensus statement on the management of chronic hepatitis B” was revised accordingly. The key terms used in the statement were also defined. The new guidelines include general management, special indications for liver biopsy in patients with persistently normal alanine aminotransferase, time to start or stop drug therapy, choice of drug to initiate therapy, when and how to monitor the patients during and after stopping drug therapy. Recommendations on the therapy of patients in special circumstances, including women in childbearing age, patients with antiviral drug resistance, concurrent viral infection, hepatic decompensation, patients receiving immune-suppressive medications or chemotherapy and patients in the setting of liver transplantation, are also included